Read on Twitter
Operation Warp Speed's Moncef Slaoui notes that there was an age difference in AstraZeneca's trial between the groups receiving the half-full dose regimen vs. two full doses.
The half-full dose, which showed 90% efficacy, had a cap at the age of 55, Slaoui says.
The half-full dose, which showed 90% efficacy, had a cap at the age of 55, Slaoui says.
"There are a number of variables we need to understand," Slaoui says.
Notes these variables could explain any difference between these two efficacy results. Also remarks the confidence intervals are wide enough where there may be no actual difference between these regimens.
Notes these variables could explain any difference between these two efficacy results. Also remarks the confidence intervals are wide enough where there may be no actual difference between these regimens.
Learning more on this will be key in figuring out if AstraZeneca's vaccine is 60%, 70%, 80%, or 90% effective. Bottom line is we really don't have a good idea still. https://www.businessinsider.com/6-key-questions-on-astrazenecas-coronavirus-vaccine-2020-11
